Details of Disease

General Information of Disease (ID: DIS31ZY6)

Disease Name	Trigeminal neuralgia
Synonyms	Tic douloureux; trifocal neuralgia; neuralgia of trigeminal nerve; trifacial neuralgia; trigeminal nerve neuralgia; trigeminal neuralgia
Disease Class	8B82: Trigeminal nerve disorder
Definition	Trigeminal neuralgia is a nerve disorder that causes a stabbing or electric-shock-like pain in parts of the face. The pain lasts a few seconds to a few minutes, and usually on only one side of the face. It can also cause muscle spasms in the face the same time as the pain. The pain may result from a blood vessel pressing against the trigeminal nerve (the nerve that carries pain, feeling, and other sensations from the brain to the skin of theface), as a complication of multiple sclerosis, or due to compression of the nerve by a tumor or cyst. In some cases, the cause is unknown. Treatment options include medicines, surgery, and complementary approaches.
Disease Hierarchy	DIS71UBB: Trigeminal nerve disorder DISEP2HK: Central and peripheral nervous disease DISFXFT7: Cranial neuralgia DISWO58J: Neuralgia DIS31ZY6: Trigeminal neuralgia
ICD Code	ICD-11 ICD-11: 8B82.0 ICD-10 ICD-10: G50.0 Expand ICD-11 '8B82.0 Expand ICD-10 'G50.0
Disease Identifiers	MONDO ID MONDO_0008599 MESH ID D014277 UMLS CUI C0040997 OMIM ID 190400 MedGen ID 21683 HPO ID HP:0100661 Orphanet ID 221091 SNOMED CT ID 31681005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Carbamazepine	DMZOLBI	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BIIB074	DMLV1ET	Phase 2	NA	[2]
Carbon dioxide intranasal	DMI42MN	Phase 2	NA	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 17 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AIF1	TT12MEP	Strong	Biomarker	[4]
ANTXR2	TTOD34I	Strong	Biomarker	[5]
CALCA	TTVSFJW	Strong	Biomarker	[6]
CPE	TTXPWO6	Strong	Biomarker	[7]
CRLF1	TT6YF5K	Strong	Biomarker	[8]
FOS	TTOM5AU	Strong	Biomarker	[4]
GFAP	TTI6FFX	Strong	Biomarker	[4]
GRIN1	TTLD29N	Strong	Biomarker	[4]
MAPK1	TT4TQBX	Strong	Posttranslational Modification	[9]
MAPK3	TT1MG9E	Strong	Altered Expression	[10]
MAPK8	TT0K6EO	Strong	Biomarker	[4]
MAPK9	TT3IVG2	Strong	Biomarker	[4]
MVD	TTE5J6X	Strong	Biomarker	[11]
PRKCG	TTRFOXJ	Strong	Biomarker	[4]
TRPM3	TTO3TD8	Strong	Biomarker	[12]
CDK5	TTL4Q97	Definitive	Biomarker	[13]
CDK5R1	TTBYM6V	Definitive	Biomarker	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DTT(s)

This Disease Is Related to 8 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AZIN2	OT8OB7CG	Strong	Biomarker	[14]
CASP8AP2	OTTWT68S	Strong	Biomarker	[8]
FEV	OTYEC4IR	Strong	Biomarker	[15]
GADL1	OTJM4A0R	Strong	Biomarker	[14]
GPN3	OTZ4584O	Strong	Genetic Variation	[16]
ORM2	OTRJGZP8	Strong	Biomarker	[6]
PRIMA1	OT9ITT3P	Strong	Genetic Variation	[17]
TENM3	OTWY13GR	Strong	Biomarker	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DOT(s)

References

1	Carbamazepine FDA Label
2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK.J Neuroinflammation. 2016 Apr 19;13(1):84. doi: 10.1186/s12974-016-0550-6.
5	In vitro and in vivo experiments of a novel intra-arterial neurovascular decompressor for treating neurovascular compression syndromes: a brief report.Neurol Res. 2019 Jul;41(7):665-670. doi: 10.1080/01616412.2019.1611009. Epub 2019 May 2.
6	Different Pain States of Trigeminal Neuralgia Make Significant Changes in the Plasma Proteome and Some Biochemical Parameters: a Preliminary Cohort Study.J Mol Neurosci. 2018 Dec;66(4):524-534. doi: 10.1007/s12031-018-1183-2. Epub 2018 Oct 17.
7	The Rare Painful Phenomena - Chronic Paroxysmal Hemicrania-tic Syndrome as a Clinically Isolated Syndrome of the Central Nervous System.Pain Physician. 2017 Feb;20(2):E315-E322.
8	Preoperative evaluation of neurovascular relationship in trigeminal neuralgia by three-dimensional fast low angle shot (3D-FLASH) and three-dimensional constructive interference in steady-state (3D-CISS) MRI sequence.Br J Radiol. 2018 May;91(1085):20170557. doi: 10.1259/bjr.20170557. Epub 2018 Feb 13.
9	Inhibitory effects of tetramethylpyrazine on pain transmission of trigeminal neuralgia in CCI-ION rats.Brain Res Bull. 2017 Sep;134:72-78. doi: 10.1016/j.brainresbull.2017.07.005. Epub 2017 Jul 11.
10	Effects of long non-coding RNA uc.48+ on pain transmission in trigeminal neuralgia.Brain Res Bull. 2019 Apr;147:92-100. doi: 10.1016/j.brainresbull.2019.02.009. Epub 2019 Feb 14.
11	Hemodynamic features of offending vessels at neurovascular contact in patients with trigeminal neuralgia and hemifacial spasm.J Neurosurg. 2018 Jul 6;130(6):1870-1876. doi: 10.3171/2018.1.JNS172544.
12	Botulinum toxin type A reduces the expression of transient receptor potential melastatin 3 and transient receptor potential vanilloid type 4 in the trigeminal subnucleus caudalis of a rat model of trigeminal neuralgia.Neuroreport. 2019 Jul 3;30(10):735-740. doi: 10.1097/WNR.0000000000001268.
13	[Expression and activity of Cdk5/p35 in a rat model of trigeminal neuropathic pain].Shanghai Kou Qiang Yi Xue. 2010 Oct;19(5):545-8.
14	Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging.Eur Radiol. 2019 May;29(5):2535-2544. doi: 10.1007/s00330-018-5804-5. Epub 2018 Nov 6.
15	Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.Cancer Imaging. 2017 May 25;17(1):15. doi: 10.1186/s40644-017-0117-5.
16	Nervus intermedius and the surgical management of geniculate neuralgia.J Neurosurg. 2018 Aug 10;131(2):343-351. doi: 10.3171/2018.3.JNS172920.
17	Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?.Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.
18	Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.Histol Histopathol. 2012 Mar;27(3):377-85. doi: 10.14670/HH-27.377.